Arrowhead Pharmaceuticals Inc. (ARWR)’s Financial Results Comparing With Cerecor Inc. (NASDAQ:CERC)

Both Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) and Cerecor Inc. (NASDAQ:CERC) are each other’s competitor in the Biotechnology industry. Thus the compare of their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Arrowhead Pharmaceuticals Inc. 94.79M 25.83 9.57M 0.07 262.60
Cerecor Inc. 19.26M 11.86 43.37M -1.19 0.00

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Arrowhead Pharmaceuticals Inc. and Cerecor Inc.

Profitability

Table 2 represents Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) and Cerecor Inc. (NASDAQ:CERC)’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Arrowhead Pharmaceuticals Inc. 10.10% 6.7% 4.3%
Cerecor Inc. -225.18% 0% 0%

Volatility & Risk

A beta of 2.06 shows that Arrowhead Pharmaceuticals Inc. is 106.00% more volatile than Standard and Poor’s 500. In other hand, Cerecor Inc. has beta of 2.17 which is 117.00% more volatile than Standard and Poor’s 500.

Liquidity

The Current Ratio and Quick Ratio of Arrowhead Pharmaceuticals Inc. are 2.3 and 2.3 respectively. Its competitor Cerecor Inc.’s Current Ratio is 1 and its Quick Ratio is 0.9. Arrowhead Pharmaceuticals Inc. can pay off short and long-term obligations better than Cerecor Inc.

Analyst Ratings

The Ratings and Recommendations for Arrowhead Pharmaceuticals Inc. and Cerecor Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Arrowhead Pharmaceuticals Inc. 0 0 1 3.00
Cerecor Inc. 0 0 2 3.00

Arrowhead Pharmaceuticals Inc. has a consensus price target of $165, and a 539.04% upside potential. Meanwhile, Cerecor Inc.’s average price target is $10.5, while its potential upside is 96.63%. Based on the analysts belief we can conclude, Arrowhead Pharmaceuticals Inc. is looking more favorable than Cerecor Inc.

Insider and Institutional Ownership

The shares of both Arrowhead Pharmaceuticals Inc. and Cerecor Inc. are owned by institutional investors at 63.9% and 51.3% respectively. Insiders owned 4.2% of Arrowhead Pharmaceuticals Inc. shares. Competitively, Cerecor Inc. has 4.9% of it’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Arrowhead Pharmaceuticals Inc. 4.58% 2.79% 10.94% 32.3% 103.5% 54.35%
Cerecor Inc. 7.23% 6.19% 20.39% 26.21% 55.52% 69.97%

For the past year Arrowhead Pharmaceuticals Inc.’s stock price has smaller growth than Cerecor Inc.

Summary

On 11 of the 12 factors Arrowhead Pharmaceuticals Inc. beats Cerecor Inc.

Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States. Its pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders. The company also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreements with Amgen, Inc. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Cerecor Inc., a clinical-stage biopharmaceutical company, develops drugs to treat patients with neurological and psychiatric disorders. It develops CERC-501, which has completed Phase II clinical trial for the adjunctive treatment of major depressive disorder (MDD), as well as to treat substance use disorders; CERC-301 that has completed Phase II clinical trial for the adjunctive treatment of patients with MDD; and CERC-406 that is in preclinical stage to treat residual cognitive impairment symptoms in patients with MDD. Cerecor Inc. also intends to develop CERC-611, a drug candidate for the treatment of partial-onset seizures in epilepsy. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Baltimore, Maryland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.